Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (ABT)
NYSE:ABT
Abbott Laboratories (ABT) Stock Price & Analysis
7,605 Followers
ABT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$88.33 - $120.40
Previous Close$102.03
Volume11.96M
Average Volume (3M)5.88M
Market Cap
$177.49B
Enterprise Value$185.66B
Total Cash (Recent Filing)$6.65B
Total Debt (Recent Filing)$14.59B
Price to Earnings (P/E)32.2
Beta0.67
Next Earnings
Oct 16, 2024EPS Estimate
$1.2Last Dividend Ex-Date
Jul 15, 2024Dividend Yield2.08%
Share Statistics
EPS (TTM)3.17
Shares Outstanding1,739,633,759
10 Day Avg. Volume6,557,564
30 Day Avg. Volume5,877,457
Standard Deviation0.06
R-Squared0.40
Alpha-0.00097
Financial Highlights & Ratios
Price to Book (P/B)25.79
Price to Sales (P/S)4.58
Price to Cash Flow (P/CF)44.90
P/FCF Ratio61.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.60
Enterprise Value/Gross Profit8.39
Enterprise Value/Ebitda17.84
Forecast
1Y Price Target
$126.30Price Target Upside23.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Abbott Laboratories News
Bulls Say, Bears Say
Bulls Say
GuidanceABT raised its 2024 guidance for sales growth and EPS and now expects 9.5-10.0% organic sales growth and $4.61-$4.71 in EPS.
Market PositionNutrition sales grew nearly 8% and should benefit from Nestle's decision to exit the US infant formula market, which leaves market share up for grabs and should ensure that ABT exits with a greater share position.
Product GrowthWith Libre, ABT continues to tap the significant opportunity for CGM utilization in basal insulin users, having secured favorable reimbursement for the indication in the US, Japan, France and Germany.
Bears Say
Foreign ExchangeFX will have an unfavorable impact of more than 2.5% on full-year reported sales.
LitigationOngoing overhang from the necrotizing enterocolitis litigation contributes to stock weakness.
Market CapEstimated loss of ~$20B in market cap since the March Reckitt NEC trial verdict.
---
Ownership Overview
2.80% Insiders
26.61% Mutual Funds
20.55% Other Institutional Investors
50.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $88.33 and its highest was $120.40 in the past 12 months.
What is Abbott Laboratories’s market cap?
Currently, no data Available
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 16, 2024 which is in 86 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 18, 2024. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.105 by $0.035.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 2.08%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is $1.2.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,739,633,800 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.14 in its last earnings report, beating expectations of $1.105. Following the earnings report the stock price went down -4.404%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Among the largest hedge funds holding Abbott Laboratories’s share is Fisher Asset Management LLC. It holds Abbott Laboratories’s shares valued at 1B.
---
Abbott Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$126.30 (23.79% Upside)
$126.30 (23.79% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Company Description
Abbott Laboratories
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
ABT Company Deck
---
ABT Earnings Call
Q2 2024
0:00 / 0:00
---
ABT Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
ABT Stock 12 Month Forecast
Average Price Target
$126.30
▲(23.79% Upside)
Technical Analysis
Best Analysts Covering ABT
1 Year
1 Year Success Rate
39/47 ratings generated profit
1 Year Average Return
+18.50%
reiterated a buy rating 3 months ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 82.98% of your transactions generating a profit, with an average return of +18.50% per trade.
---